CCT5 and cancer: CCT5 demonstrates higher expression levels in immune cells, particularly Tprolif (Proliferating T cell), CD4Tconv (Conventional CD4 T cells), Treg (Regulatory T cells), CD8T (CD8 T cells), CD8Tex (Exhausted CD8 T cells), NK cells, B cells, Plasma cells, DC (Dendritic cells), and Mono/Macro (Monocytes or macrophages), compared with stromal cells like fibro blasts, endothelial cells, and myofibroblasts, in most cancers (Fig. 7B).